431 studies found for:    "Lupus"
Show Display Options
Rank Status Study
1 Unknown  Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus
Conditions: Cutaneous Lupus;   Discoid Lupus;   Lupus;   Systemic Lupus Erythematosus
Interventions: Drug: AMG811;   Drug: AMG811 Placebo
2 Completed Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions
Conditions: Lupus Erythematosus, Discoid;   Lupus Erythematosus, Systemic
Interventions: Drug: R932333;   Drug: Placebo
3 Recruiting A Non-drug Study Profiling Cutaneous Lupus
Conditions: Lupus Erythematosus, Cutaneous;   Lupus Erythematosus, Systemic;   Lupus Erythematosus, Discoid
Interventions: Procedure: No intervention, skin biopsy;   Procedure: No intervention, blood collection;   Procedure: No intervention, urine collection
4 Recruiting A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
Conditions: Lupus Erythematosus, Cutaneous;   Lupus Erythematosus, Systemic;   Lupus Erythematosus, Discoid;   Healthy
Interventions: Procedure: Skin biopsy;   Procedure: Blood collection;   Procedure: Urine collection
5 Completed Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease
Conditions: Immunologic Diseases;   Autoimmune Diseases;   Systemic Lupus Erythematosus;   Lupus Nephritis;   Lupus Glomerulonephritis
Intervention: Drug: Abetimus sodium (LJP 394)
6 Completed A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus
Conditions: Lupus Erythematosus, Cutaneous;   Lupus Erythematosus, Systemic
Interventions: Drug: 1 mg/kg CNTO 136;   Drug: 4 mg/kg CNTO 136;   Drug: 10 mg/kg CNTO 136;   Drug: Placebo
7 Unknown  Cutaneous Lupus Erythematosus and Elidel
Conditions: Lupus Erythematosus, Cutaneous;   Lupus Erythematosus, Discoid
Intervention: Drug: Elidel (pimecrolimus)
8 Not yet recruiting Phase Ib Study of SC Milatuzumab in SLE
Conditions: Lupus Erythematosus, Cutaneous;   Lupus Erythematosus, Discoid;   Lupus Erythematosus, Systemic;   Lupus Vasculitis, Central Nervous System;   Lupus Nephritis
Intervention: Drug: milatuzumab
9 Completed Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion
Condition: Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus
Interventions: Drug: hydroxychloroquine (Z0188);   Drug: Placebo
10 Terminated Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus
Conditions: Cutaneous Lupus;   Lupus
Interventions: Drug: AMG 557;   Drug: AMG 557 Placebo
11 Active, not recruiting Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis
Conditions: Lupus Nephritis;   Lupus Erythematosus, Systemic
Interventions: Drug: Abatacept;   Drug: cyclophosphamide;   Drug: azathioprine;   Drug: prednisone;   Drug: abatacept placebo;   Drug: azathioprine placebo
12 Recruiting Study of Systemic Lupus Erythematosus
Conditions: Lupus Nephritis;   Systemic Lupus Erythematosus
Intervention:
13 Completed Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
Conditions: Lupus Erythematosus, Systemic;   Lupus Nephritis
Interventions: Drug: CTLA4-IgG4m (RG2077);   Drug: Cyclophosphamide
14 Terminated Study of LJP 394 in Lupus Patients With History of Renal Disease
Conditions: Lupus Erythematosus, Systemic;   Lupus Nephritis
Interventions: Drug: abetimus sodium (LJP 394) and/or placebo solution;   Drug: abetimus sodium (LJP 394);   Drug: Phosphate-buffered saline
15 Recruiting Safety Study of AMG 557 in Subjects With Lupus Arthritis
Condition: Lupus Arthritis, Systemic Lupus Erythematosus
Interventions: Drug: AMG 557;   Drug: Matching Placebo
16 Completed Cyclophosphamide and Fludarabine to Treat Lupus Nephritis
Conditions: Glomerulonephritis;   Lupus Nephritis;   Systemic Lupus Erythematosus
Intervention: Drug: SQ Fludarabine
17 Completed Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study
Conditions: Systemic Lupus Erythematosus;   Lupus Nephritis
Interventions: Drug: Cyclosporine A;   Drug: Cyclophosphamide
18 Completed Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis
Conditions: Lupus Nephritis;   Lupus Erythematosus, Systemic
Intervention: Drug: tacrolimus
19 Terminated TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )
Conditions: Lupus Erythematosus, Systemic;   Lupus Nephritis
Interventions: Drug: infliximab;   Drug: placebo
20 Not yet recruiting Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis
Condition: Systemic Lupus Erythematosus, Lupus Nephritis
Interventions: Drug: Oral prednisolone;   Drug: Rituximab;   Drug: Mycophenolate mofetil;   Drug: Methyl prednisolone

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years